Summary The tolerability and efficacy of four courses of paclitaxel and ifosfamide plus cisplatin every 3 weeks was evaluated in patients with residual or refractory ovarian cancer. Additionally, supportive haematological effects of recombinant human interleukin 3 (rhlL-3) and recombinant human granulocyte colony-stimulating factor (G-CSF) were studied. Paclitaxel starting dose was 135 mg m-2 (day 1), with ifosfamide dose 1.2 g m-2 day-1 (days 2-4) and cisplatin dose 30 mg m-2 day-1 (days 2-4). All 16 patients received 5.0 9g kg-1 day-' G-CSF (days 7-16) and, in addition, eight patients were randomized to receive 10 gg kg-' day-' rhlL-3 (days 5-9). Paclitaxel and ifosfamide doses were reduced when grade IV haematological toxicity occurred. In the absence of grade IV haematological toxicity and normal recovery of haematopoiesis, paclitaxel dose was escalated. Toxicity was evaluable in 56 courses, with haematological effects in 52. Despite antiemetic treatment, nausea and vomiting (2 grade 1) occurred in 50 courses. Five patients had persisting peripheral neuropathy. Renal and liver function were not affected. Grade IV neutropenia occurred in 12 out of 52 courses, with neutropenic fever in two patients, both of whom died from fatal septicaemia. Grade IV thrombocytopenia without bleeding was observed in 15 courses. Grade IV haematological toxicity was associated with hepatic metastases and concurrent increases in alkaline phosphatase (P <0.001) and gamma-glutamyltransferase (P=0.007). No relation was found between haematological toxicity and pharmacokinetic parameters of paclitaxel. Patients treated with rhlL-3 showed a tendency to a faster platelet recovery (not affecting platelet nadir), and the cisplatin dose intensity was higher (P=0.025). Six of the nine evaluable patients had a tumour response. The overall median progression-free survival was 7 months and the overall mean survival was 13 months. In conclusion, this potentially interesting combination as second-line treatment showed a low tolerability with unexpected mortality, while rhlL-3 administration tended to induce a more rapid platelet recovery.
The prognosis of patients with advanced epithelial ovarian cancer is poor and long-term survivors are scarce. This has urged the continuous search for new therapies. In this respect, paclitaxel is an interesting drug which has been added recently to the armamentarium against ovarian cancer. It is non-cross-resistant with cisplatin in vitro (Kelland and Abel, 1992) and in vivo (Gore et al., 1995) , and it has an unique mechanism of action by which cell growth is inhibited.
Increased response rates after dose-intensified paclitaxel administration have been suggested by several phase I and II studies (Eisenhauer et al, 1994; Kohn et al, 1994) . Neutropenia is the most frequent dose-limiting haematological toxicity after paclitaxel (Trimble et al, 1993) . Granulocyte colony-stimulating factor (G-CSF) administration following paclitaxel results in reduction of neutropenic episodes, including nadir depth, allowing increases in paclitaxel dose (Sarosy et al, 1992; Kohn et al, 1994; Schiller et al, 1994) . Combination of paclitaxel with other effective chemotherapeutic drugs might be an alternative approach to improve response rates. A rational step would be to combine paclitaxel with cisplatin, the most active agent in ovarian cancer. In vitro, this combination has demonstrated marked synergism (Untch et al, 1994) in a sequence-dependent way (Jekunen et al, 1994; Vanhoefer et al, 1995) . Recently, improved response rates, diseasefree survival and overall survival were demonstrated after paclitaxel and cisplatin combination therapy in first-line treatment for ovarian cancer compared with cisplatin and cyclophoshamide (McGuire et al, 1996) .
We designed a feasibility study as second-line treatment for patients with residual or relapsing ovarian cancer. Paclitaxel was combined with cisplatin and ifosfamide, as the latter has demonstrated activity in cisplatin-resistant ovarian cancer (Sutton et al, 1989; Markman et al, 1992) . In order to reduce dose-limiting neutropenia, all patients received recombinant methionyl human granulocyte colony-stimulating factor (G-CSF). Thrombocytopenia, uncommon after paclitaxel alone, was expected because of the addition of ifosfamide to the chemotherapeutic regimen. Therefore, the effects of the addition of recombinant human interleukin 3 (rhIL-3) were evaluated in a randomized way compared with G-CSF alone. Preclinical Lu et al, 1988; 703 Teramura et al, 1988) and clinical studies Postmus et al, 1992; Veldhuis et al, 1995) have demonstrated that rhIL-3 is a stimulator of thrombopoiesis. The combination of rhIL-3 and G-CSF acts synergistically in stimulating haematopoiesis in vitro (Ottmann et al, 1989; Takaue et al, 1990) . It is postulated that rhIL-3 induced stimulation of immature non-committed haematopoietic cells results in increased numbers of more committed haematopoietic cells responsive for G-CSF. Based on these preclinical observations rhIL-3 was administered before G-CSF. Paclitaxel pharmacokinetic assessment was performed in the last seven patients after unpredictable haematological toxicity had occurred. In this paper, the tolerability, feasibility and efficacy of a novel paclitaxel-based combination therapy is presented and, in addition, the value of the addition of rhIL-3 before G-CSF is described.
PATIENTS AND METHODS
All patients, aged 18-75 years, had histology-proven epithelial ovarian carcinoma, had undergone appropriate surgical staging and debulking, whenever possible, and had received first-line, platinum-containing chemotherapy. Patients with residual disease after or progressive disease during first-line chemotherapy and patients with recurrences within 1 year after the last chemotherapy regimen were eligible. A maximum of two prior chemotherapy regimens was permitted, and patients had to have an evaluable tumour. A leucocyte count of . 3 x 109 1-' and a platelet count of > 100 x 109 1-' were required at entry. Patients with severe heart, lung, liver (serum bilirubin . 40 gmol 1-') or renal impairment (creatinine clearance <60 ml min-') were excluded from the study, as were patients with a WHO performance score grade III-IV and those with atopy or any history of serious allergies.
Study design
Randomization was performed at entry between the combination (arm A) of G-CSF (Filgrastim, Amgen, Thousand Oaks, CA, USA) and rhIL-3 (Sandoz, Basle, Switzerland) or G-CSF alone (arm B). Chemotherapy consisted of paclitaxel (Bristol-Myers Squibb, Regensburg, Germany), cisplatin (Bristol-Myers Squibb, Latina, Italy) and ifosfamide (Asta Medica, Bielefeld, Germany). The administration schedule of chemotherapy and haematopoietic growth factors is shown in (1993) . The plasma disappearance curves were modelled by using the Kinfit computer software (MW/Pharm, Medi/ware, Groningen, The Netherlands) as reported by Proost and Meijer (1992) . A, G-CSF + rhlL-3; B, G-CSF; CT, chemotherapy. 0  1800  90  2  0  2  -2  75  2400  90  2  1  3  -1  100  3000  90  2  5  7  0  135  3600  90  8  13  21  1  150  3600  90  7  4  11  2  165  3600  90  4  4  8  3  175  3600  90  2  2  4 variables between both groups, and the Spearman rank analysis was used for correlation coefficients. All P-values are two-sided, only P-values <0.05 were considered significant. Median progression-free survival (PFS) and mean overall survival (OS) were calculated with Kaplan-Meier survival analysis.
RESULTS
Sixteen patients were randomized, eight in each arm. The main characteristics and laboratory values at entry are listed in Table 2 .
Overall, the disease parameters, bone marrow, liver and renal function were equally balanced for both patient groups. A total of 56 courses were evaluable for toxicity, 27 in arm A and 29 in arm B (Table 2) . Fifty-two courses, 27 in arm A and 25 in arm B, were available to evaluate haematological effects. The median follow-up period was 12 months (range 9-16 months). Chemotherapy dose intensity
In Table 3 , the doses of the combinations are listed for all courses. The median interval between the courses was 3 weeks (range 3-5 weeks) for arm A and 4 weeks (range 3-5 weeks) for arm B (P=0.03). The number of 3-week courses was 18 out of 26 (69%) in arm A and 11 out of 25 (44%) in arm B, there were seven 4-week courses in both arms, one 5-week course in arm A and seven in arm B (P=0.046). The mean (± s.e.m.) delivered paclitaxel dose, calculated per week, was 40 ± 3 mg m-2 in arm A and 34 ± 2 mg m-2 in arm B. Ifosfamide dose per week was 1033 ± 52 mg m-2 for arm A vs 940 ± 47 mg m-2 for arm B (not significant, NS). The calculated weekly cisplatin dose was 27.5 ± 0.8 mg m-2 in arm A and 24.5 ± 1.0 mg m-2 in arm B (P=0.025).
Toxicity
Five patients prematurely discontinued the study. Two patients died during treatment, one in course 4, day 12 (arm B) and one in course 1, day 10 (arm B). Both had proven neutropenic septicaemia, with hypotension and renal failure which had developed acutely. Another patient experienced bleeding from a large liver metastasis in the second course (arm B), two patients withdrew their consent after 2 and 3 courses (both in arm A). One patient switched from arm A to arm B after the first course, and the remaining courses in this patient were therefore only evaluable for toxicity. The major non-haematological toxic events are summarized in Table 4 . All patients experienced alopecia. One patient collapsed during the first minutes of the first paclitaxel infusion (arm A) and regained normal control spontaneously; the paclitaxel was stopped and restarted at a slower infusion rate during the first 30 min of the paclitaxel infusion. One day after paclitaxel infusion, facial erythema, which subsided within 2 days, was observed in all patients. Nausea and vomiting requiring additional antiemetic therapy (ondansetron, metoclopramide) was reported by 12 patients and occurred in all courses. Three patients had transient nausea and vomiting and one patient experienced nausea without vomiting. Nausea and vomiting had disappeared by day 9 of each course (as reported by the majority of the patients). Seven patients complained of numbness and paraesthesias in fingers and toes which disappeared before the next course (WHO grade I); in four of these patients (arm A), the symptoms started after course 1. These symptoms persisted and/or worsened in five patients after course 4 (peripheral neuropathy WHO grade II). Two patients experienced walking ataxia, lasting for more than 3 months. No relation was found between the occurrence of peripheral neurotoxicity and the extent of prior treatment. Central neurotoxicity was not observed at any time during the study. Headache was reported by six patients, five from arm A and one from arm B. Other constitutional symptoms were fatigue and myalgia which were considered mild to moderate. Headache and fatigue were most pronounced during the days following chemotherapy administration, including the days rhIL-3 was administered.
Gastrointestinal symptoms were observed infrequently as shown in Table 3 and were mild never exceeding WHO grade II. One patient experienced an intra-abdominal bleeding from a large hepatic metastasis, and chemotherapy was stopped after this episode. The bleeding started on day 3 of the second course; at that moment, the platelet count was 93 x 109 1-and there were no signs of clotting disorders. Deep venous thrombosis occurred in one patient during rhIL-3 administration (day 9) in course 1 and rhIL-3 was therefore discontinued and i.v. heparin and oral anticoagulants were started. In the third course, again, deep venous thrombosis was diagnosed, this time in the contralateral leg despite optimal anticoagulant therapy. Physical examination and ultrasonography revealed no evidence of recurrent disease in the first and second episode.
Haematology
As all patients received the same dose of chemotherapy in the course 1, the haematological effects of rhIL-3 were analysed in this course.
The mean number of leucocytes and neutrophils are shown in Figure 1 and 2 respectively. The leucocyte nadir, observed day 9 in both arms, was 3.7 ± 0.6 x 109 1-1 (mean±s.e.m.) for arm A and 2.9 ± 0.8 x 109 1-1 for arm B. The neutrophil nadir was 2.2 ± 0.5 x 109 1-' and 2.4 ± 1.1 x 109 1-1 (mean±s.e.m.) and occurred day 9 in arm A and day 12 in arm B respectively (both NS). The recovery of leucocytes and neutrophils tended to be faster for arm A, but, as for the nadir, these differences were not statistically significant. Grade IV leucopenia (<1 x 109 1-1) occurred in 5 out of 27 courses for arm A (n=3, including neutropenic sepsis) and 5 out of 25 courses in arm B (n=4, also including one sepsis). The median duration of grade IV leucopenia to leucocytes > 3 x 109 1-1 was <6 days and was the same for both arms. Grade IV neutropenia (Figure 3 ), however no statistical significance was reached. Grade IV thrombocytopenia (<25 x 109 1-') was observed in 9 out of 27 vs 6 out of 25 courses for arm A and B respectively (NS). The number of prophylactic platelet transfusions was similar in both arms, namely 9 out of 27 courses (n=3) in arm A versus 6 out of 25 courses (n=3) in arm B. The median number of platelet transfusions required was respectively 2 (range 1-5) and 1.5 (range 1-7) for arm A and B (NS). The median time from platelets below 20 x 109 1-1 to recover to above 2 100 x 109 1-' was <3 days (range 3-6) for arm A and <4 days (range 3-6) for arm B (NS).
Biochemistry
During the study, no changes were observed in liver and renal function tests in individual patients. Courses with and without grade IV leuco-and thrombocytopenia were compared with respect to liver and renal function parameters (obtained on day 1 of the involved course), i.e. AF, y-GT, AST, ALT, total bilirubin and serum creatinine. The results of this analysis are shown in Table 5 . Serum levels of AF, y-GT,-total bilirubin and creatinine were significantly higher for the courses in which grade IV leucoand/or thrombocytopenia was observed. These differences in renal and liver function were not related to the previous chemotherapy dose, as the dose administered was higher in courses in which no grade IV leuco-and thrombocytopenia had occurred (Table 4) . No statistically significant differences with regard to these parameters could be found at entry between patients who had experienced an episode of grade IV leuco-and thrombocytopenia and those who had not. However, all patients with liver metastases (n=4) developed grade IV haematological toxicity, whereas only 4 out of 12 patients without liver involvement developed haematological toxicity of this grade (NS). 
Pharmacokinetics
The PK parameters are listed in Table 6 . Patients 1, 2 and 7 received a paclitaxel dose (Dpaci) of 75, 100 and 175 mg m-2, respectively, and the remaining patients received a dose of 135 mg m-2. Because of the known non-linearity of the pharmacokinetic parameters (Huizing et al, 1993) , no normalization was performed and the data for the different doses are given. Tumour response Seven patients were not evaluable for tumour response as, in five patients with microscopic disease at entry, no laparotomy was performed after chemotherapy, and two patients died prematurely. Of the remaining nine patients, three achieved stable disease (one in arm A and two in arm B), three a partial response (all arm B) and three patients were found to have a complete clinical response (two in arm A and one in arm B). The total response rate in evaluable patients was therefore 67%. In 11 patients, CA-125 levels were obtained; in two of these, the CA-125 level increased during treatment, all the others demonstrated a decrease. In responders, the mean CA-125 level decreased by 88% vs a 62% decrease in non-responders (NS).
The mean PFS for responding, non-responding and non-evaluable patients was 7 months (95% confidence interval (CI) 6-8 months), 5 months (95% CI 3-6 months) and 8 months (95% CI 5-12 months) respectively (P=0.04, log rank). The median OS was not reached during the follow-up of 9-16 months, the average OS of this group of patients was 13+ months (95% CI 10-15 months, Figure 4 ).
DISCUSSION
Short-lasting grade IV neutropenia after this combination therapy was observed in 6 out of 16 patients (27%), a relatively low frequency compared with other reports such as those with reported incidences above 50% after paclitaxel monotherapy (Einzig et al, 1992; Sarosy et al, 1992; Trimble et al, 1993; Thigpen et al, 1994) . After cisplatin-paclitaxel combination therapy, the incidence of grade IV neutropenia was 78% (McGuire et al, 1996) . Two out of sixteen patients (12.5%) in our study, however, died during treatment because of neutropenic septicaemia. This is a high mortality compared with paclitaxel monotherapy (135 mg m-2, every 3 weeks) in which a 1.6% mortality was reported (Trimble et al, 1994) . Remarkably, in our study no neutropenic fever, septicaemia nor renal impairment was observed in the other patients. The complication of severe bone marrow depression seems therefore rather unpredictable. The tolerability of this regimen was primarily determined by nausea, vomiting and neurotoxicity. Grade III nausea and vomiting requiring additional antiemetic therapy was quite substantial. Sensory neurotoxicity was observed in 7 out of 16 patients (44%) and in five patients these symptoms persisted after discontinuation of the chemotherapy, resulting in an ataxic gait in two of them. A varying incidence of neurotoxicity has been reported for paclitaxel (4-52%) (Eisenhauer et al, 1994; Thigpen et al, 1994) , for cisplatin (3-92%) (Cersosimo, 1989) and for the combination of paclitaxel and cisplatin (27-28%) (Rowinsky et al, 1991 , McGuire et al, 1996 . Both paclitaxel and cisplatin induced neurotoxicity are cumulative and dose related (Cersosimo, 1989; Sarosy et al, 1992; Eisenhauer et al, 1994) . Paclitaxel dose >250 mg m-2 is strongly associated with the occurrence of neurotoxicity, which is dose limiting at doses >300 mg m-2 (Sarosy et al, 1992) . Cisplatin-induced neurotoxicity is mainly observed after cumulative doses of 300 mg m-2 (Cersosimo, 1989) . Rowinsky et al (1991) found a 27% incidence of neurotoxicity (n=44) for the combination of cisplatin and paclitaxel, compared with 44% in our study. Their doses were 200 and 75 mg m-2, our maximal doses were of 175 and 90 mg m-2 for paclitaxel and cisplatin respectively. The frequency of persistent neurotoxicity was higher in patients treated with rhIL-3 (NS). Direct effects of rhIL-3 on the peripheral nerve system have not been reported. The dose intensity of cisplatin was somewhat higher in group A, which may have affected the incidence of neurotoxicity.
Deep venous thrombosis occurred twice in one patient. After the first event, rhIL-3 was discontinued. The symptoms, however, recurred despite adequate anticoagulant therapy. Arterial thrombosis associated with rhIL-3 has been reported in the literature (Theodossiou et al, 1994) . No thromboembolic events were reported by Trimble et al (1993) in their paper on approximately 1000 patients treated with paclitaxel only. However, recently Sevelda et al (1994) reported thrombosis in three patients after paclitaxel treatment. rhIL-3 related toxicity mainly consisted of flu-like symptoms and was similar to other clinical studies Postmus et al, 1992; Biesma et al, 1993; D'Hondt et al, 1993; Veldhuis et al, 1995) . The principal effects obtained with rhIL-3 administration in this regimen are a shorter treatment interval and a higher delivered cisplatin dose. There is a tendency for a faster platelet recovery for patients treated with rhIL-3. This did, however, not affect the incidence of grade IV thrombocytopenia and the number of platelet transfusions. Reduction of chemotherapy-induced myelosuppression by rhIL-3 has been observed earlier (D'Hondt et al, 1993; Veldhuis et al, 1995) .
Grade IV leuco-and thrombocytopenia were related to the presence of hepatic metastases and increases in serum alpha fetoprotein (AF) and gamma-glutamyltransferase (y-GT). Whether these increases in AF and y-GT affected paclitaxel metabolism and excretion remains to be established, as no correlation could be found with PK parameters. However, the number of patients in our study was probably too small to discriminate. Others have suggested that increases in AF and y-GT may affect metabolism and excretion of paclitaxel (Huizing et al, 1995) .
A tumour response was observed in six out of nine evaluable patients. Response rates of larger monotherapy paclitaxel studies varied between 16% and 48% (Einzig et al, 1992; Eisenhauer et al, 1994; Kohn et al, 1994; Pearl et al, 1994; Thigpen et al, 1994) . Median progression-free survival and overall survival were in line with data obtained after paclitaxel monotherapy (Einzig et al, 1992; Eisenhauer et al, 1994; Kohn et al, 1994; Pearl et al, 1994; Thigpen et al, 1994) .
In this small feasibility study, the combination of paclitaxel with cisplatin and ifosfamide resulted in a relatively high response rate for a second-line regimen in refractory patients. Toxicity was, however, substantial and therefore this regimen should not be promoted for patients with advanced and platinum-refractory ovarian cancer. As the principal aim of this study was to obtain data on tolerability and efficacy, no cost-benefit analysis was performed.
rhIL-3-related effects revealed a tendency to a higher platelet nadir count and faster platelet recovery. The presence of hepatic metastases and decreased liver excretory function, as indicated by increased cholestatic parameters, may enhance the incidence of grade IV haematopoietic toxicity because of decreased excretion of paclitaxel and ifosfamide, this should be taken into account when selecting patients for paclitaxel combination treatment.
